Medicure (CVE:MPH) Reaches New 12-Month High – Here’s What Happened

Shares of Medicure Inc. (CVE:MPH) hit a new 52-week high during trading on Tuesday . The company traded as high as C$2.60 and last traded at C$2.55, with a volume of 10238 shares trading hands. The stock had previously closed at C$2.55.

Medicure Stock Performance

The company’s fifty day moving average is C$1.29 and its 200 day moving average is C$1.18. The company has a market capitalization of C$26.72 million, a P/E ratio of -3.56 and a beta of 0.44. The company has a current ratio of 0.97, a quick ratio of 1.28 and a debt-to-equity ratio of 6.02.

Medicure Company Profile

Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.